IMAGE: Lung squamous cell carcinoma

Breaking News

Key: Meeting M      Journal J      Funder F

Showing releases 976-1000 out of 1332.

<< < 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 > >>

Public Release: 10-Dec-2014
2014 San Antonio Breast Cancer Symposium
German breast group study: Superior activity for nab-paclitaxel in early breast cancer
German Breast Group Ph III study demonstrates superior activity for nab-paclitxel vs conventional paclitaxel in early, high-risk breast cancer, and utility of pCR (pathological complete response) as a surrogate marker for long-term efficacy

Contact: Peggy C. Frank
pfrank@frankpr.com
818-642-6804
Initiate PR

Public Release: 10-Dec-2014
2014 San Antonio Breast Cancer Symposium
Early trial of new drug shows promise for patients with triple-negative breast cancer
In patients with metastatic triple-negative breast cancer, infusion of pembrolizumab produced durable responses in almost one out of five patients. One of the 27 patients had a complete response and four had a partial response. Seven more patients had stable disease.
Merck

Contact: John Easton
john.easton@uchospitals.edu
773-795-5225
University of Chicago Medical Center

Public Release: 10-Dec-2014
JAMA
Most women with early-stage breast cancer in US receive radiation for too long
Two-thirds of women treated for early-stage breast cancer in the US receive longer radiation therapy than necessary, according to a new study published in JAMA this week from Penn Medicine researchers Ezekiel J. Emanuel, M.D., Ph.D., and Justin E. Bekelman, M.D.
Anthem, Inc., NIH/National Cancer Institute

Contact: Steve Graff
stephen.graff@uphs.upenn.edu
215-349-5653
University of Pennsylvania School of Medicine

Public Release: 9-Dec-2014
2014 San Antonio Breast Cancer Symposium
Three new Myriad studies highlighted at 2014 San Antonio Breast Cancer Symposium
Three new Myriad studies presented at the 2014 San Antonio Breast Cancer Symposium found that the myRisk Hereditary Cancer test detected 105 percent more mutations in cancer causing genes than conventional BRCA testing alone; the myChoice HRD test accurately predicted response to platinum-based therapy in patients with early-stage triple negative breast cancer and the BRACAnalysis test significantly predicted response to platinum-based drugs in patients with metastatic triple negative breast cancer.

Contact: Ronald Rogers
rrogers@myriad.com
801-584-3065
Myriad Genetics, Inc.

Public Release: 9-Dec-2014
Annals of Epidemiology
Smoking still causes large proportion of cancer deaths in the United States
A new American Cancer Society study finds that despite significant drops in smoking rates, cigarettes continue to cause about three in ten cancer deaths in the United States.
NIH/National Cancer Institute, American Cancer Society

Contact: David Sampson
david.sampson@cancer.org
American Cancer Society

Public Release: 9-Dec-2014
2014 San Antonio Breast Cancer Symposium
Common chemotherapy is not heart toxic in patients with BRCA1/2 mutations
Use of anthracycline-based chemotherapy, a common treatment for breast cancer, has negligible cardiac toxicity in women whose tumors have BRCA1/2 mutations -- despite preclinical evidence that such treatment can damage the heart.
National Institutes of Health

Contact: Karen Teber
km463@georgetown.edu
215-514-9751
Georgetown University Medical Center

Public Release: 9-Dec-2014
Molecular Cancer Therapeutics
Data published on ANG4043, anti-HER2 monoclonal antibody for treatment of brain metastases
Data published in Molecular Cancer Therapeutics, entitled 'ANG4043, a Novel Brain-penetrant Peptide-mAb Conjugate, is Efficacious against HER2-positive Intracranial Tumors in Mice,' demonstrates that ANG4043, a peptide-monoclonal antibody conjugate, entered the brain at therapeutic concentrations, resulting in significantly prolonged survival in mice. The antibody is directed against HER2, which is the protein targeted by Herceptin. The data published shows that this technology to cross the blood brain barrier is applicable to biologics such as mAbs.
Angiochem

Contact: Kathryn Morris
kathryn@theyatesnetwork.com
914-204-6412
The Yates Network

Public Release: 9-Dec-2014
Journal of Nuclear Medicine
Nuclear medicine treatment shows promise for cancer therapy
Cancer therapy can be much more effective using a new way to customize nuclear medicine treatment, researchers say in the December 2014 issue of The Journal of Nuclear Medicine. The process could also be useful for other diseases that could benefit from targeted radiation.

Contact: Kimberly Brown
kbrown@snmmi.org
703-652-6773
Society of Nuclear Medicine

Public Release: 9-Dec-2014
56th American Society of Hematology Annual Meeting
Possible genetic link found in treatment-related cognitive issues in children with leukemia
Common variations in four genes related to brain inflammation or cells' response to damage from oxidation may contribute to the problems with memory, learning and other cognitive functions seen in children treated for acute lymphoblastic leukemia, according to a research presented at the meeting of the American Society of Hematology. The findings suggest the possibility of screening ALL patients for their risk of long-term treatment-related effects on memory, attention and learning and studying potential interventions.
St. Baldrick's Foundation, Michael J. Garil Fund for Leukemia Research, National Insitutes of Health

Contact: Irene Sege
irene.sege@childrens.harvard.edu
617-919-3110
Dana-Farber Cancer Institute

Public Release: 9-Dec-2014
Metallomics
Metal test could help diagnose breast cancer early
It may be possible to develop a simple blood test that, by detecting changes in the zinc in our bodies, could help to diagnose breast cancer early.

Contact: University of Oxford News Office
news.office@admin.ox.ac.uk
44-186-528-0528
University of Oxford

Public Release: 9-Dec-2014
Annals of Internal Medicine
Women with dense breasts will have to look beyond ultrasound for breast cancer screening
Supplemental ultrasound screening for all US women with dense breasts would substantially increase healthcare costs with little improvement in overall health, according to a Dartmouth-led research study.
NIH/National Cancer Institute

Contact: Kirk Cassels
kirk.A.Cassels@Hitchcock.org
603-653-6177
The Geisel School of Medicine at Dartmouth

Public Release: 9-Dec-2014
International Journal of Radiation Oncology • Biology • Physics
Analysis shows increased use of HF-WBI for patients with early-stage breast cancer
The use of hypofractionated whole-breast irradiation for patients with early-stage breast cancer increased 17.4 percent from 2004 to 2011, and patients are more likely to receive hypofractionated whole-breast irradiation compared to conventionally fractionated whole-breast irradiation when they are treated at an academic center or live less than or equal to 50 miles away from a cancer center, according to a study published in the Dec. 1, 2014 issue of the International Journal of Radiation Oncology • Biology • Physics.

Contact: Michelle Kirkwood
press@astro.org
703-286-1600
American Society for Radiation Oncology

Public Release: 9-Dec-2014
Journal of National Cancer Institute
Mayo Clinic: Genotyping errors plague CYP2D6 testing for tamoxifen therapy
Clinical recommendations discouraging the use of CYP2D6 gene testing to guide tamoxifen therapy in breast cancer patients are based on studies with flawed methodology and should be reconsidered, according to the results of a Mayo Clinic study published in the Journal of the National Cancer Institute.
National Institutes of Health, Mayo Clinic, Breast Cancer Research Foundation

Contact: Joe Dangor
newsbureau@mayo.edu
507-284-5005
Mayo Clinic

Public Release: 9-Dec-2014
Nicotine & Tobacco Research
E-cigarettes less addictive than cigarettes
E-cigarettes appear to be less addictive than cigarettes for former smokers and this could help improve understanding of how various nicotine delivery devices lead to dependence, according to researchers.
NIH/National Institute on Drug Abuse, US Food and Drug Administration

Contact: Matt Solovey
msolovey@hmc.psu.edu
717-531-8606
Penn State

Public Release: 9-Dec-2014
Annals of Otology, Rhinology & Laryngology
Long-term results confirm success of MGH-developed laser treatment for vocal-cord cancer
The first long-term study of a pioneering endoscopic laser treatment for early vocal-cord cancer, developed at Massachusetts General Hospital and previously shown to provide optimal voice outcomes, finds that it is as successful as traditional approaches in curing patients' tumors while avoiding the damage to vocal quality caused by radiotherapy or by conventional laser or cold-instrument surgery.
National Philanthropic Trust, 'V' Foundation, Eugene B. Casey Foundation, Voice Health Institute

Contact: Mike Morrison
mdmorrison@partners.org
617-724-6425
Massachusetts General Hospital

Public Release: 9-Dec-2014
2014 San Antonio Breast Cancer Symposium
James Ingle of Mayo Clinic Recognized for Breast Cancer Research
James Ingle, M.D., an internationally recognized breast cancer expert, will receive the 2014 William L. McGuire Memorial Lecture Award on Dec. 10 at the 2014 San Antonio Breast Cancer Symposium.

Contact: Joe Dangor
newsbureau@mayo.edu
507-284-5005
Mayo Clinic

Public Release: 8-Dec-2014
Improving health through smarter cities: Debut of a major new global science collaboration
A new international program to promote health in cities through better urban design and policies debuts at an international meeting of world experts in health, environmental, behavioral and social sciences hosted by the Chinese Academy of Sciences, Xiamen, China Tuesday Dec. 9.

Contact: Terry Collins
tc@tca.tc
416-538-8712
United Nations University

Public Release: 8-Dec-2014
Nature Structural & Molecular Biology
CNIO team has visualized the DNA double-strand break process for the first time
Scientists from the Spanish National Cancer Research Centre, led by Guillermo Montoya, have developed a method for producing biological crystals that has allowed scientists to observe -- for the first time -- DNA double chain breaks. They have also developed a computer simulation that makes this process, which lasts in the order of millionths of a second, visible to the human eye. The study is published today by the journal Nature Structural & Molecular Biology.

Contact: Nuria Noriega
comunicacion@cnio.es
Centro Nacional de Investigaciones Oncologicas (CNIO)

Public Release: 8-Dec-2014
Nature Genetics
A yardstick to measure the malignancy of prostate cancer
A protein that influences the epigenetic characteristics of tumor cells is directly linked to the grade of malignancy of prostate cancer. This key discovery has been made by a team of scientists from the German Cancer Research Center, the University of Zurich, Hamburg-Eppendorf University Hospital, Heidelberg University, and other institutes. The detection of this biomarker may serve as an indicator of the likelihood that the disease may take an aggressive course, and may thus be helpful in choosing an appropriate treatment.

Contact: Christoph Plass
c.plass@dkfz.de
49-622-142-1300
University of Zurich

Public Release: 8-Dec-2014
Proceedings of the National Academy of Sciences
Toughest breast cancer may have met its match
Triple-negative breast cancer is as bad as it sounds. The cells that form these tumors lack three proteins that would make the cancer respond to powerful, customized treatments. Instead, doctors are left with treating these patients with traditional chemotherapy drugs that only show long-term effectiveness in 20 percent of women with triple-negative breast cancer.
Department of Defense (Maryland Department of Health and Mental Hygiene, Cindy Rosencrans Fund for Triple Negative Breast Cancer, Women Together Fighting Cancer Organization, NIH/National Cancer Institute

Contact: Cathy Kolf
ckolf@jhmi.edu
443-287-2251
Johns Hopkins Medicine

Public Release: 8-Dec-2014
Journal of Clinical Oncology
Experience counts with radiation therapy for head and neck cancer, study shows
Radiation therapy for head and neck cancer is highly complex, and a new study published in the Journal of Clinical Oncology with an accompanying editorial suggests that medical centers with more experience centers have better patient outcomes.
NIH/National Cancer Institute

Contact: Darrell E. Ward
darrell.ward@osumc.edu
614-293-3737
Ohio State University Wexner Medical Center

Public Release: 8-Dec-2014
Nature Communications
Turning biological cells to stone improves cancer and stem cell research
A simple technique that creates near-perfect, robust models of human and animal cells is being used to study cancer and stem cells, and could be used to create complex durable structures without the use of machinery.
US Department of Energy's Basic Energy Sciences

Contact: Neal Singer
nsinger@sandia.gov
505-845-7078
DOE/Sandia National Laboratories

Public Release: 8-Dec-2014
JAMA Pediatrics
Hookah smoking increases risk of subsequent cigarette smoking among adolescents
A team of researchers at Dartmouth College and University of Pittsburgh found respondents who had smoked water pipe tobacco but not smoked cigarettes were at increased risk of cigarette smoking two years later as recently published online in JAMA Pediatrics.
NIH/National Cancer Institute, NIH/National Center for Advancing Translational Sciences

Contact: Kirk Cassel
Kirk.A.Cassels@Hitchcock.org
603-653-6177
The Geisel School of Medicine at Dartmouth

Public Release: 8-Dec-2014
Blood
PRM-151 therapy well tolerated in patients with advanced myelofibrosis
A study that investigated the potential of the compound PRM-151 for reducing progressive bone marrow fibrosis in patients with advanced myelofibrosis has shown initial positive results. Myelofibrosis is a life-threatening bone marrow cancer.
Promedior Inc., National Institutes of Health

Contact: Ron Gilmore
rlgilmore1@mdanderson.org
713-745-1898
University of Texas M. D. Anderson Cancer Center

Public Release: 8-Dec-2014
Nature Biotechnology
Injectable 3-D vaccines could fight cancer and infectious diseases
Researchers at the Wyss Institute for Biologically Inspired Engineering at Harvard University and Harvard's School of Engineering and Applied Sciences show a non-surgical injection of programmable biomaterial that spontaneously assembles in vivo into a 3-D structure could fight and even help prevent cancer and also infectious disease such as HIV.

Contact: Kat J. McAlpine
katherine.mcalpine@wyss.harvard.edu
617-432-8266
Wyss Institute for Biologically Inspired Engineering at Harvard

Showing releases 976-1000 out of 1332.

<< < 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 > >>

  Search News Releases

     

Featured Multimedia

 

EurekAlert!